There is one clinical trial.
In the United Kingdom, there are currently 138,000 confirmed patients with coronavirus, causing 18,738 deaths. Whilst the disease may be mild in the majority of patients, a significant proportion of patients require intensive care therapy and a ventilator due to lung injury. In addition to lung injury/failure (acute respiratory distress syndrome (ARDS)), around 50% of patients admitted to intensive care develop acute kidney injury (AKI) (requiring advanced support via haemofiltration) and multi-organ failure. It is unclear why patients suffering from COVID-19 develop such severe lung injury (requiring life support or ventilation) or indeed why patients develop other organ dysfunction such as kidney injury. The investigators hypothesis that this may due to an over-reaction of the immune system particularly in the lungs. This then results in the release of various mediators and biological messengers which can be pushed into the blood bloodstream (exacerbated by positive pressure generated by the ventilator). These mediators then travel, via the blood, to other organs such as the kidney where they cause inflammation and injury of cells, resulting in organ failure. At the Imperial College London (specifically at the Hammersmith Hospital campus) the investigators are in the unique position to investigate the pathophysiology of multi-organ failure as we are a referral centre for patients with COVID-19 who have developed renal and multi-organ failure (the hospital has accepted a number of these patients from various hospitals across the region). The Division of Anaesthetics, Pain Medicine and Intensive Care at Imperial College London, headed by Professor Masao Takata, has an international reputation, investigating the mechanisms of organ injury and failure (particularly lung injury) in critical care patients (non-viral causes). The investigators would like to apply well-established methods to try and further the scientific community's knowledge of this severe and deadly viral condition. The investigators hope that this would lead to the development of medication that would treat this deadly virus.
Description: This will involve measurement of microvesicles in bloodMeasure: Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19 Time: 18 months
Description: This will involve measurement of microvesicles in bronchoalveolar lavage fluidMeasure: Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19 Time: 18 months
Description: This will involve measurement of microvesicles in urineMeasure: Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19 Time: 18 months
Description: The aforementioned inflammatory markers will be correlated with level fo lung injury which will be based upon the level of oxygen required by patients.Measure: Correlation of inflammatory mediators in the bronchoalveolar lavage fluid with extent of lung injury (e.g. based upon oxygen requirement) Time: 18 months
Description: The aforementioned inflammatory markers will be measured in renal outcomes (creatinine and urine output) and cardiovascular markers (e.g. natriuretic peptides (BNP and NT pro-BNP) and Troponin).Measure: Correlation of circulating inflammatory mediators with renal and cardiovascular markers Time: 18 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports